Di X, Martinez-Tellez B, Krekels E, Jurado-Fasoli L, Osuna-Prieto F, Ortiz-Alvarez L
J Clin Endocrinol Metab. 2023; 109(5):1351-1360.
PMID: 37967236
PMC: 11031222.
DOI: 10.1210/clinem/dgad668.
Baenas I, Sole-Morata N, Granero R, Fernandez-Aranda F, Pujadas M, Mora-Maltas B
Eur Psychiatry. 2023; 66(1):e97.
PMID: 37937379
PMC: 10755577.
DOI: 10.1192/j.eurpsy.2023.2460.
Kajero J, Seedat S, Ohaeri J, Akindele A, Aina O
Discov Ment Health. 2023; 2(1):18.
PMID: 37861864
PMC: 10501030.
DOI: 10.1007/s44192-022-00021-2.
Baenas I, Miranda-Olivos R, Granero R, Sole-Morata N, Sanchez I, Pastor A
Eur Psychiatry. 2023; 66(1):e49.
PMID: 37254556
PMC: 10305007.
DOI: 10.1192/j.eurpsy.2023.2411.
Cortes-Justo E, Garfias-Ramirez S, Vilches-Flores A
Islets. 2023; 15(1):1-11.
PMID: 36598083
DOI: 10.1080/19382014.2022.2163826.
An Innovative Sandwich Type Biosensor towards Sensitive and Selective Monitoring of 2-Arachidonoylglycerol in Human Plasma Samples Using P(-CD)-AuNPs-DDT as Amplificant Agent: A New Immuno-Platform for the Recognition of Endocannabinoids in Real....
Aletaha N, Ghaseminasab K, Hasanzadeh M, Kohansal F, Liu Y, Seidi F
Biosensors (Basel). 2022; 12(10).
PMID: 36290931
PMC: 9599568.
DOI: 10.3390/bios12100791.
Obesity risk is associated with brain glucose uptake and insulin resistance.
Pekkarinen L, Kantonen T, Rebelos E, Latva-Rasku A, Dadson P, Karjalainen T
Eur J Endocrinol. 2022; 187(6):917-928.
PMID: 36288097
PMC: 9782452.
DOI: 10.1530/EJE-22-0509.
The Endocannabinoid System and Physical Activity-A Robust Duo in the Novel Therapeutic Approach against Metabolic Disorders.
Charytoniuk T, Zywno H, Berk K, Bzdega W, Kolakowski A, Chabowski A
Int J Mol Sci. 2022; 23(6).
PMID: 35328503
PMC: 8948925.
DOI: 10.3390/ijms23063083.
Obesity risk is associated with altered cerebral glucose metabolism and decreased μ-opioid and CB receptor availability.
Kantonen T, Pekkarinen L, Karjalainen T, Bucci M, Kalliokoski K, Haaparanta-Solin M
Int J Obes (Lond). 2021; 46(2):400-407.
PMID: 34728775
PMC: 8794779.
DOI: 10.1038/s41366-021-00996-y.
The Current and Potential Application of Medicinal Cannabis Products in Dentistry.
Lowe H, Toyang N, Steele B, Bryant J, Ngwa W, Nedamat K
Dent J (Basel). 2021; 9(9).
PMID: 34562980
PMC: 8466648.
DOI: 10.3390/dj9090106.
The effects of cannabis and cannabinoids on the endocrine system.
Meah F, Lundholm M, Emanuele N, Amjed H, Poku C, Agrawal L
Rev Endocr Metab Disord. 2021; 23(3):401-420.
PMID: 34460075
DOI: 10.1007/s11154-021-09682-w.
Cerebral μ-opioid and CB receptor systems have distinct roles in human feeding behavior.
Kantonen T, Karjalainen T, Pekkarinen L, Isojarvi J, Kalliokoski K, Kaasinen V
Transl Psychiatry. 2021; 11(1):442.
PMID: 34453034
PMC: 8397789.
DOI: 10.1038/s41398-021-01559-5.
The feeding behaviour of Amyotrophic Lateral Sclerosis mouse models is modulated by the Ca -activated K 3.1 channels.
Cocozza G, Garofalo S, Morotti M, Chece G, Grimaldi A, Lecce M
Br J Pharmacol. 2021; 178(24):4891-4906.
PMID: 34411281
PMC: 9293222.
DOI: 10.1111/bph.15665.
Analysis of Both Lipid Metabolism and Endocannabinoid Signaling Reveals a New Role for Hypothalamic Astrocytes in Maternal Caloric Restriction-Induced Perinatal Programming.
Tovar R, Vargas A, Aranda J, Sanchez-Salido L, Gonzalez-Gonzalez L, Chowen J
Int J Mol Sci. 2021; 22(12).
PMID: 34208173
PMC: 8230792.
DOI: 10.3390/ijms22126292.
What Role Does the Endocannabinoid System Play in the Pathogenesis of Obesity?.
Schulz P, Hryhorowicz S, Rychter A, Zawada A, Slomski R, Dobrowolska A
Nutrients. 2021; 13(2).
PMID: 33530406
PMC: 7911032.
DOI: 10.3390/nu13020373.
Endocannabinoid System Components as Potential Biomarkers in Psychiatry.
Navarrete F, Garcia-Gutierrez M, Jurado-Barba R, Rubio G, Gasparyan A, Austrich-Olivares A
Front Psychiatry. 2020; 11:315.
PMID: 32395111
PMC: 7197485.
DOI: 10.3389/fpsyt.2020.00315.
The Endocannabinoid System as Pharmacological Target Derived from Its CNS Role in Energy Homeostasis and Reward. Applications in Eating Disorders and Addiction.
Viveros M, Bermudez-Silva F, Lopez-Rodriguez A, Wagner E
Pharmaceuticals (Basel). 2020; 4(8):1101-1136.
PMID: 32143540
PMC: 4058662.
DOI: 10.3390/ph4081101.
Novel CB1 receptor antagonist BAR-1 modifies pancreatic islet function and clinical parameters in prediabetic and diabetic mice.
Nava-Molina L, Uchida-Fuentes T, Ramos-Tovar H, Fregoso-Padilla M, Rodriguez-Monroy M, Vega A
Nutr Diabetes. 2020; 10(1):7.
PMID: 32132523
PMC: 7055595.
DOI: 10.1038/s41387-020-0110-0.
Glucose Increase DAGLα Levels in Tanycytes and Its Inhibition Alters Orexigenic and Anorexigenic Neuropeptides Expression in Response to Glucose.
Palma-Chavez A, Konar-Nie M, Ordenes P, Maurelia F, Elizondo-Vega R, Oyarce K
Front Endocrinol (Lausanne). 2019; 10:647.
PMID: 31620093
PMC: 6763563.
DOI: 10.3389/fendo.2019.00647.
Dual inhibition of cannabinoid CB receptor and inducible NOS attenuates obesity-induced chronic kidney disease.
Udi S, Hinden L, Ahmad M, Drori A, Iyer M, Cinar R
Br J Pharmacol. 2019; 177(1):110-127.
PMID: 31454063
PMC: 6976880.
DOI: 10.1111/bph.14849.